Endocrine effects in female weight lifters who self-administer testosterone and anabolic steroids

[1]  M. B. Wallace,et al.  Effects of Anabolic Steroids on Lipoprotein Profiles of Female Weight Lifters. , 1990, The Physician and sportsmedicine.

[2]  C. Nilsson,et al.  Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis. , 1989, The Journal of clinical endocrinology and metabolism.

[3]  C. Yesalis,et al.  Epidemiological and Policy Issues in the Measurement of the Long Term Health Effects of Anabolic-Androgenic Steroids , 1989, Sports medicine.

[4]  G. Sinnecker,et al.  Sex hormone-binding globulin response to the anabolic steroid stanozolol: evidence for its suitability as a biological androgen sensitivity test. , 1989, The Journal of clinical endocrinology and metabolism.

[5]  P. Thompson,et al.  Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. , 1989, JAMA.

[6]  J. Wilson,et al.  Androgen abuse by athletes. , 1988, Endocrine reviews.

[7]  D. Katz,et al.  Affective and psychotic symptoms associated with anabolic steroid use. , 1988, The American journal of psychiatry.

[8]  L. Demers,et al.  Declining Adrenal Androgens: An Association with Bone Loss in Aging Women , 1987, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[9]  M. Alen,et al.  Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes , 1987, The American journal of sports medicine.

[10]  G. Hammond,et al.  A liquid-phase immunoradiometric assay (IRMA) for human sex hormone binding globulin (SHBG). , 1985, Journal of steroid biochemistry.

[11]  R. Strauss,et al.  Anabolic steroid use and perceived effects in ten weight-trained women athletes. , 1985, JAMA.

[12]  G. Finerman,et al.  Side Effects of Anabolic Steroids in Weight-Trained Men. , 1983, The Physician and sportsmedicine.

[13]  S. Haffner,et al.  Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. , 1983, Metabolism: clinical and experimental.

[14]  W. Malarkey,et al.  Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. , 1977, Cancer research.

[15]  W. Malarkey,et al.  Disordered nocturnal prolactin regulation in women with breast cancer. , 1977, Cancer research.

[16]  Landry Gl,et al.  Anabolic steroid abuse , 1990 .

[17]  Robert E. Jones,et al.  High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. , 1990, Metabolism: clinical and experimental.

[18]  O. Jänne,et al.  The androgen-induced phenotype. , 1990, NIDA research monograph.

[19]  K. Friedl.  Reappraisal of the health risks associated with the use of high doses of oral and injectable androgenic steroids. , 1990, NIDA research monograph.

[20]  M. Massobrio,et al.  61 Dehydroepiandrosterone sulphate concentrations in breast duct fluid , 1985 .